Old Web
English
Sign In
Acemap
>
authorDetail
>
S. Michel
S. Michel
Boston Children's Hospital
Internal medicine
Medicine
Ivacaftor
Lumacaftor
Sweat chloride
3
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV1 ≥ 90% predicted at baseline
2020
Journal of Cystic Fibrosis
B.L. Aalbers
K.M. de Winter-de Groot
H.G.M. Arets
R.W. Hofland
A.C. de Kiviet
M.M.M. van Oirschot-van de Ven
M.A. Kruijswijk
S. Schotman
S. Michel
C.K. van der Ent
Harry G.M. Heijerman
Show All
Source
Cite
Save
Citations (5)
Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males.
2020
Journal of Cystic Fibrosis
B.L. Aalbers
R.W. Hofland
I. Bronsveld
K.M. de Winter-de Groot
H.G.M. Arets
A.C. de Kiviet
M.M.M. van Oirschot-van de Ven
M.A. Kruijswijk
S. Schotman
S. Michel
C.K. van der Ent
Harry G.M. Heijerman
Show All
Source
Cite
Save
Citations (4)
Rationale and design of the HIT-CF organoid study: stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators
2020
Peter van Mourik
S. Michel
Annelotte M. Vonk
Jeffrey M. Beekman
Cornelis K. van der Ent
Show All
Source
Cite
Save
Citations (3)
1